Ignite Creation Date:
2025-12-24 @ 5:21 PM
Ignite Modification Date:
2025-12-27 @ 6:46 AM
Study NCT ID:
NCT03084250
Status:
UNKNOWN
Last Update Posted:
2017-05-03
First Post:
2017-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
Sponsor:
Shanghai Nanhui Nanhua Hospital
Organization:
Study Overview
Official Title:
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
Status:
UNKNOWN
Status Verified Date:
2017-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The CHB subjects who are cirrhosis, will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Detailed Description:
This study is a prospective, randomized, open-label study.
The CHB subjects who are cirrhosis will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
The CHB subjects who are cirrhosis will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: